A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression

NCT05189197 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma(DLBCL)

Interventions

DRUG: Zanubrutinib + R-CHOP

Sponsor

Fudan University

Collaborators

[object Object]
[object Object]
[object Object]